Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease

AIDS

Volumn 27, Issue 15, 2013, Pages 2335-2344

  Ghezzi, Silvia ^a   Galli, Laura ^b   Kajaste Rudnitski, Anna ^a   Turrini, Filippo ^a   Marelli, Sara ^a   Toniolo, Daniela ^c   Casoli, Claudio ^d,e   Riva, Agostino ^d   Poli, Guido ^c,f   Castagna, Antonella ^b   Vicenzi, Elisa ^a  

^a Viral Pathogens and Biosafety Unit   (Italy)

^b Department of Infectious Diseases ^*  (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e GEMIB Laboratory   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

HIV 1 disease; HIV 1 long terminal repeat driven transcription; HIV 1 replication; Single nucleotide polymorphisms; Tripartite motif containing 22

Indexed keywords

PHYTOHEMAGGLUTININ; PROTEIN; RENILLA LUCIFERIN 2 MONOOXYGENASE; TRIPARTITE MOTIF CONTAINING 22; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS INHIBITION;

ADULT; DISEASE PROGRESSION; FEMALE; HAPLOTYPES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 84884502126     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432474.76873.5f     Document Type: Article

References (37)

1. Han K, Lou DI, Sawyer SL. Identification of a genomic reservoir for new TRIM genes in primate genomes. PLoS Genet 2011; 7:e1002388.
2. Short KM, Cox TC. Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. J Biol Chem 2006; 281:8970-8980.
3. Sardiello M, Cairo S, Fontanella B, Ballabio A, Meroni G. Genomic analysis of the TRIM family reveals two groups of genes with distinct evolutionary properties. BMC Evol Biol 2008; 8:225.
4. Sawyer SL, Emerman M, Malik HS. Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog 2007; 3:e197.
5. Hattlmann CJ, Kelly JN, Barr SD. TRIM22: a diverse and dynamic antiviral protein. Mol Biol Int 2012; 2012:153415.
6. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427:848-853.
7. Towers GJ. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007; 4:40.
8. Tissot C, Mechti N. Molecular cloning of a new interferoninduced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem 1995; 270: 14891-14898.
9. Bouazzaoui A, Kreutz M, Eisert V, Dinauer N, Heinzelmann A, Hallenberger S, et al. Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages. Virology 2006; 356:79-94.
10. Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 2008; 4:e1000007.
11. Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, et al. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaBresponsive long terminal repeat elements. J Virol 2011; 85: 5183-5196.
12. Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol 2011; 85: 208-216.
13. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, et al. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog 2010; 6:e1000781.
14. Gonzalez N, Perez-Olmeda M, Mateos E, Cascajero A, Alvarez A, Spijkers S, et al. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother 2010; 65:2493-2501.
15. Koup RA, Ho DD, Poli G, Fauci AS. Isolation and quantitation of HIV in peripheral blood. Curr Protoc Immunol 2001, Chapter 12: Unit 12.2, edited by John E Coligan.
16. Brambilla AM, Castagna A, Nocita B, Hasson H, Boeri E, Veglia F, et al. Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections. J Acquir Immune Defic Syndr 2001; 27:44-48.
17. Vicenzi E, Bagnarelli P, Santagostino E, Ghezzi S, Alfano M, Sinnone MS, et al. Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood 1997; 89: 191-200.
18. Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, Broggini V, et al. Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS 2006; 20:567-574.
19. Tarkowski M, Ferraris L, Martone S, Strambio de Castillia F, Misciagna D, Mazzucchelli RI, et al. Expression of interleukin-15 and interleukin-15Ralpha in monocytes of HIV type 1-infected patients with different courses of disease progression. AIDS Res Hum Retroviruses 2012; 28:693-701.
20. Guergnon J, Dalmasso C, Broet P, Meyer L, Westrop SJ, Imami N, et al. Single-nucleotide polymorphism-defined class I and class III major histocompatibility complex genetic subregions contribute to natural long-term nonprogression in HIV infection. J Infect Dis 2012; 205:718-724.
21. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993; 341:441.
22. revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
23. Capua I, Kajaste-Rudnitski A, Bertoli E, Vicenzi E. Pandemic vaccine preparedness: have we left something behind? PLoS Pathog 2009; 5:e1000482.
24. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575.
25. Parry DA. Hendecad repeat in segment 2A and linker L2 of intermediate filament chains implies the possibility of a righthanded coiled-coil structure. J Struct Biol 2006; 155:370-374.
26. Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol 2012; 13:214-222.
27. MacMicking JD. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol 2012; 12:367-382.
28. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-650.
29. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451:425-430.
30. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic- and myeloid-cellspecific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474:654-657.
31. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, et al. SAMHD1 restricts HIV-1 infection in resting CD4 (+) T cells. Nat Med 2012; 18:1682-1687.
32. Biswas P, Poli G, Orenstein JM, Fauci AS. Cytokine-mediated induction of human immunodeficiency virus (HIV) expression and cell death in chronically infected U1 cells: do tumor necrosis factor alpha and gamma interferon selectively kill HIV-infected cells? J Virol 1994; 68:2598-2604.
33. Napolitano LM, Meroni G. TRIM family: pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life 2012; 64:64-71.
34. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7:798-812.
35. Anastassopoulou CG, Kostrikis LG. The impact of human allelic variation on HIV-1 disease. Curr HIV Res 2003; 1:185-203.
36. Walker BD. Elite control of HIV infection: implications for vaccines and treatment. Top HIV Med 2007; 15:134-136.
37. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011; 6:181-187.